Fecal calprotectin, MMP-9, and human beta-defensin-2 levels in pediatric inflammatory bowel disease

International Journal of Colorectal Disease

Volumn 29, Issue 1, 2014, Pages 43-50

  Kolho, Kaija Leena ^a   Sipponen, Taina ^b   Valtonen, Elsa ^a   Savilahti, Erkki ^a  

^a UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Children; Colitis ulcerative; Crohn's disease; Fecal markers

Indexed keywords

BETA DEFENSIN 2; CALGRANULIN; GELATINASE B; HUMAN BETA DEFENSIN 2; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANEMIA; ARTICLE; CHILD; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; DISEASE ACTIVITY; ENDOSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS; YOUNG ADULT;

ADOLESCENT; BETA-DEFENSINS; BIOLOGICAL MARKERS; CHILD; FECES; FEMALE; HUMANS; INFANT; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MATRIX METALLOPROTEINASE 9; ROC CURVE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84891883478     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-013-1775-9     Document Type: Article

References (33)

1. Turunen P, Kolho KL, Auvinen A, Iltanen S, Huhtala H, Ashorn M (2006) Incidence of inflammatory bowel disease in Finnish children, 1987-2003. Inflamm Bowel Dis 12:677-683 (Pubitemid 44253750)
2. Rutgeerts P, Vermeire S, Van Assche G (2007) Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 56:453-455 (Pubitemid 46580492)
3. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Farkkila M (2008) Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 14:40-46 (Pubitemid 351196867)
4. Bunn SK, Bisset WM, Main MJ, Golden BE (2001) Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 32:171-177 (Pubitemid 32280632)
5. Konikoff MR, Denson LA (2006) Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 12:524-534
6. Baugh MD, Perry MJ, Hollander AP, Davies DR, Cross SS, Lobo AJ, et al. (1999) Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 117:814-822 (Pubitemid 29468223)
7. Makitalo L, Sipponen T, Kärkkäinen P, Kolho KL, Saarialho-Kere U (2009) Changes in matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinases (TIMP) expression profile in Crohn's disease after immunosuppressive treatment correlate with histological score and calprotectin values. Int J Colorectal Dis 24:1157-1167
8. Makitalo L, Rintamaki H, Tervahartiala T, Sorsa T, Kolho KL (2012) Serum MMPs 7-9 and their inhibitors during glucocorticoid and anti-TNF-therapy in pediatric inflammatory bowel disease. Scand J Gastroenterol 47:785-794
9. Annahazi A, Molnar T, Farkas K, Rosztóczy A, Izbéki F, Gecse K, et al. (2013) Fecal MMP-9: a new noninvasive differential diagnostic and activity marker in ulcerative colitis. Inflamm Bowel Dis 19:316-320. doi: 10.1002/ibd.22996
10. Langhorst J, Junge A, Rueffer A, Wehkamp J, Foell D, Michaelsen A, Musial F, Dobos GJ (2009) Elevated human β-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol 104:404-410
11. Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J, et al. (1999) Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 286:525-528
12. Voss E, Wehkamp J, Wehkamp K, Stange EF, Schröder JM, Harder J (2006) NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J Biol Chem 281:2005-2011 (Pubitemid 43845788)
13. Lennard-Jones JE (1989) Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 170:2-6 (Pubitemid 20015811)
14. Kolho KL, Alfthan H, Hämäläinen E (2012) Effect of bowel cleansing for colonoscopy on fecal calprotectin levels in pediatric patients. J Pediatr Gastroenterol Nutr 55:751-753
15. Kolho KL, Raivio T, Lindahl H, Savilahti E (2006) Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol 41:720-725 (Pubitemid 43995015)
16. Sipponen T, Kolho K-L (2010) Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand J Gastroenterol 45:872-877
17. Hämäläinen A, Sipponen T, Kolho K-L (2011) Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels. World J Gastroenterol 17:5166-5171
18. Kolho KL, Turner D (2013) Fecal calprotectin and clinical disease activity in pediatric ulcerative colitis.ISRN Gastroenterol. 2013:179024. doi: 10.1155/2013/179024.
19. Savilahti EM, Kukkonen AK, Haahtela T, Tuure T, Kuitunen M, Savilahti E (2012) Intestinal defensin secretion in infancy is associated with the emergence of sensitization and atopic dermatitis. Clin Exp Allergy 42:405-411
20. Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, et al. (2007) Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 133:423-433 (Pubitemid 47193130)
21. Turner D, Seow CH, Greenberg GR, Griffiths AM, Silverberg MS, Steinhart AH (2009) A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol 7:1081-1088
22. Hyams J, Markowitz J, Otley A, Rosh J, Mack D, Bousvaros A, Kugathasan S, Pfefferkorn M, Tolia V, Evans J, Treem W, Wyllie R, Rothbaum R, del Rosario J, Katz A, Mezoff A, Oliva-Hemker M, Lerer T, Griffiths A, Pediatric Inflammatory Bowel Disease Collaborative Research Group (2005) Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr 41:416-421 (Pubitemid 41407602)
23. Haapamäki J, Roine RP, Sintonen H, Kolho KL (2011) Health-related quality of life in paediatric patients with inflammatory bowel disease related to disease activity. J Paediatr Child Health 47:832-837
24. Sipponen T, Savilahti E, Kärkkäinen P, Kolho KL, Nuutinen H, Turunen U, Färkkilä M (2008) Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 14:1392-1398
25. Molander P, af Björkesten CG, Mustonen H, Haapamäki J, Vauhkonen M, Kolho KL, Färkkilä M, Sipponen T (2012) Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm Bowel Dis 18:2011-2017
26. Shaoul R, Sladek M, Turner D, Paerregaard A, Veres G, Wauters G, et al. (2012) Limitations of fecal calprotectin at diagnosis in untreated pediatric Crohn's disease. Inflamm Bowel Dis 18:1493-1497
27. Henderson P, Casey A, Lawrence SJ, Kennedy NA, Kingstone K, Rogers P, Gillett PM, Wilson DC (2012) The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease. Am J Gastroenterol 107:941-949
28. Mäkitalo L, Kolho KL, Karikoski R, Anthoni H, Saarialho-Kere U (2010) Expression profiles of matrix metalloproteinases and their inhibitors in colonic inflammation related to pediatric inflammatory bowel disease. Scand J Gastroenterol 45:862-871
29. Matsuno K, Adachi Y, Yamamoto H, Goto A, Arimura Y, Endo T, Itoh F, Imai K (2003) The expression of matrix metalloproteinase matrilysin indicates the degree of inflammation in ulcerative colitis. J Gastroenterol 38:348-354 (Pubitemid 36626270)
30. Rath T, Roderfeld M, Graf J, Wagner S, Vehr AK, Dietrich C, Geier A, Roeb E (2006) Enhanced expression of MMP-7 and MMP-13 in inflammatory bowel disease: a precancerous potential? Inflamm Bowel Dis 12:1025-1035 (Pubitemid 44665472)
31. Wehkamp J, Harder J, Wehkamp K, Wehkamp-von Meissner B, Schlee M, Enders C, et al. (2004) NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun 72:5750-5758 (Pubitemid 39303685)
32. Kofla-Dlubacz A, Matusiewicz M, Iwanczak B (2012) Correlation of MMP-3 and MMP-9 with Crohn's disease activity in children. Dig Dis Sci 57:706-712
33. Lakatos G, Hritz I, Varga MZ, Juhász M, Miheller P, Cierny G, Tulassay Z, Herszényi L (2012) The impact of matrix metalloproteinases and their tissue inhibitors in inflammatory bowel diseases. Dig Dis 30:289-295